Document Detail


Disabling inflammatory pathways with biologics and resulting clinical outcomes in severe asthma.
MedLine Citation:
PMID:  23289846     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Patients with severe asthma have a significant unmet need with persistent symptoms and/or frequent exacerbations despite high intensity treatment. These severe unrelenting symptoms have a huge impact on heathcare resources due to frequent hospital admissions and requirement for intensive and expensive medications. There is a compelling need for more effective and safer therapies to help severe asthma sufferers to achieve adequate control of their disease.
AREAS COVERED: Expanding knowledge of innate and adaptive immune responses has led to development of new biologic approaches for severe asthma. Here, the authors will review the existing efficacy and safety data from clinical trials of some of the new biologic therapies that are in development for severe asthma. Their specific role in distinctively targeted subpopulations of severe asthmatics will be also discussed.
EXPERT OPINION: Defining and phenotyping severe asthma patients will become increasingly important as some patients who were previously classified as having severe asthma may become well-controlled with a targeted phenotype-specific treatment. However, pharmacoeconomic concerns should also be taken into account given the elevated acquisition costs of recombinant human monoclonals and of the diagnostic screening procedures for the identification of potential responders.
Authors:
Massimo Caruso; Emanuele Crisafulli; Shirin Demma; Stephen Holgate; Riccardo Polosa
Related Documents :
7418666 - Inhibition of amygdaloid kindling by chronic pretreatment with cocaine or methamphetamine.
15132126 - Clinical and attentional effects of acute nicotine treatment in tourette's syndrome.
23583566 - Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves pe...
24304726 - Clinical, economic, and humanistic burden of asthma in canada: a systematic review.
21694856 - Irritable bowel syndrome: diagnostic approaches in clinical practice.
18804946 - Symptom prevalence and longitudinal follow-up in cancer outpatients receiving chemother...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-07
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  13     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-11     Completed Date:  2013-07-25     Revised Date:  2014-02-20    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  393-402     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Asthmatic Agents / therapeutic use*
Asthma / drug therapy*
Biological Products / therapeutic use*
Humans
Inflammation / prevention & control*
Signal Transduction / drug effects*
Treatment Outcome
Grant Support
ID/Acronym/Agency:
G0800766//Medical Research Council
Chemical
Reg. No./Substance:
0/Anti-Asthmatic Agents; 0/Biological Products

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Bone-healing pattern at the surface of titanium implants: an experimental study in the dog.
Next Document:  Comparative In Vitro Susceptibility of Besifloxacin and Seven Comparators Against Ciprofloxacin- and...